AzTrials
AzTrials

Congenital Heart DiseaseNCT00772135

Reversibility by Sildenafil of Exercise-Induced Abnormal Right Ventricular Pressure Response in ASD and VSD-Operated Patients

A study testing sildenafil citrate in people with Congenital Heart Disease, run by Oslo University Hospital at 1 site in Norway.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether oral sildenafil citrate reduces the abnormal right ventricular pressure response during exercise in adolescent and adult patients with specific types of congenital heart defects. Read more about this study

Who is it for?
Ages 16 to 25 years
Conditions the study is for
Congenital Heart Disease
What is being tested?
sildenafil citrate
Type of treatment
Pill or oral medicine
How many people
15 participants
Where
1 siteNorway
Study dates
Sep 2008to Apr 2009
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 25 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Exercise right ventricular systolic pressure of 45 mm Hg or above.
  • Operated for atrial septal defect or ventricular septal defect or minimal defect not operated or minimal residual defect.

Who cannot join

  • Acute infectious/febrile illness,
  • Significant mental or physical disability preventing reliable exercise testing

Trial locations and contacts

1 site in 1 country.

Erik Thaulow, professor Dr Med contact

+47 23074537

erik.thaulow@rikshospitalet.no

Henrik Holmstrom, dr med contact

+47 23074541

henrik.holmstrom@rikshospitalet.no

Norway1 site, 1 recruiting
  • Rikshospitalet University Hospital

    Oslo, Oslo, 0027

    Henrik Brun, MD, +4723074554, henrik.brun@rikshospitalet.no

    per morten fredriksen, dr scient, +4723072277, per.morten.fredriksen@rikshospitalet.no

    Recruiting

Other trials in Norway

About this study

Official title: Pulmonary Hypertension in Adolescents and Adults With Congenital Heart Disease

The purpose of this study is to determine whether oral sildenafil citrate reduces the abnormal right ventricular pressure response during exercise in adolescent and adult patients with specific types of congenital heart defects.

Read the detailed description

13.3 Study design and protocol

13.3.1 Design: double-blind case-control cross-over study

13.3.2 Patients inclusion / exclusion criteria:

The study consists of 12-16 patients from the main study (see main protocol) who are selected by following criteria

  • Abnormal right ventricular pressure response to exercise (cut-off 45 mmHg maximal RVSP during exercise)
  • Informed consent to participation including use of sildenafil / placebo. The patients will be approximately one year older than during the initial study.

13.3.3 Examination protocol

The patients will be examined similarly twice with at least 12 hours and one night sleep between these activities to ensure drug washout. One hour before each study part, a pharmacy produced capsule (envelope coded and drawn in a random manner from a box) containing either sildenafil citrate 50 mg or placebo will be administered. In this manner each patient will be tested once with placebo use and once with sildenafil use respectively.

The participant is taken to a clinical exercise physiology laboratory for testing separated by a night's sleep and at least 12 hours.

Monitoring equipment is mounted during the period of drug absorbtion and distribution.

  1. One minute handgrip static exercise is performed as described with 80% of maximal strength applied. BP response is registered beat to beat.
  2. Pulmonary function is examined, including pulmonary volumes (single breath, technical description see below), and spirometry
  3. Cardiopulmonary exercise testing according to main protocol (see 3.8)
  4. Exercise echocardiography during supine bicycle exercise is performed as described in main protocol (see 3.7). Other monitoring during supine cycle exercise:
  5. ECG
  6. Diffusion capacity is monitored (intra breath, technical description below). For equipment calibration haemoglobin concentration is measured by fingertip blood sampling before and after cycle exercise.
  7. Cardiac output and peripheral oxygen saturation is continuously monitored by Task Force Monitor (see below)
  8. Pulmonary function testing is repeated
  9. Handgrip testing is repeated as in 1.

Difffusion capacity monitoring There are two ways of measuring diffusion capacity using SensorMedics V-max analyzing system (Yorba Linda, CA, USA) - intra breath and single breath.

Measurements of forced vital capacity (FVC), forced expiratory volume (FEV1), FEV1 ratio (FEV1/FVC), peak expiratory flow (PEF), total lung capacity (TLC or VA), diffusion capacity for carbon monoxide (TLCO), adjusted diffusing capacity (TLCO/VA), residual volume (RV), capillary blood volume (Vc) and membrane conductance (Dm) are included in the analysis and will be performed according to European Respiratory Society standards.

Single breath The diffusion capacity is used to estimate the amount of gas travelling from lungs to the bloodstream across the membrane. In the process methane (CH4) is used in the concentration of 0.3 %, 0.3 % carbon monoxide (CO), 21 % oxygen (O2) and nitrogen (N2). In the estimation of TLCO several measurements are included; 1) the area of gas transportation between alveoli and the capillaries (A), 2) the wall thickness (membrane) between the alveoli and the erythrocytes (T), 3) the amount of haemoglobin available (Hb) and 4) the reaction rate of CO too Hb (θ) are determinants for the amount of CO that manage to diffuse across to the blood57.

In the process CH4 is used as a marker, as it does not diffuse across to the blood but become diluted. CH4 mixes with the residual volume in the lungs, and the degree of dilution is used to calculate alveoli volume. CO diffuses across to the blood in addition to become diluted. By measuring the amount of CO and CH4 in the expiration air compared to the inhaled gas, after a hold of breath in 8-10 seconds, we get an expression for the diffusion capacity in the lungs.

Figure 1: The single-breath method for TLCO Intra breath Intra breath reefers to the continuous real-time measurement of carbon monoxide uptake by the pulmonary capillary blood during a single breath maneuver. Intra breath maneuver may be performed during exercise.

The calibration procedure samples to set the span points to 0.3 % CO and 0.3 % CH4 (methane). The patient starts with normal breathing and is then instructed to exhale as much as possible - then inhale completely. After total inhalation the patient should exhale at a slow even flow until the computer end the test. The test window shows gas concentration versus time and volume versus time tracing in real time during the maneuver. The flow versus time curve is shown simultaneously. The collection interval used in the calculation of the TLCO is extending from 20 - 80 % of the exhaled volume (marked area in figure 2).

Figure 2. The intra breath method for TLCO

The patients need to practice this maneuver at rest before using it during exercise. The exhalation time is reduced during exercise, but the patients must try to exhale as slowly as they can in order for the analysis to be correct.

Cardiopulmonary monitoring and analysis When analysing changes in vascular resistances during exercise a measurement of pressure is only a part of the hemodynamic picture. According to Ohms law, blood flow measurement is necessary to conclude about the vascular resistances. For this purpose, a non-invasive cardiac stroke volume analyser based on thoracic impedance technique, will be used.(Task Force Monitor, CNS systems, product description enclosed) This equipment is validated for cardiac output monitoring as compared with thermodilution as gold standard. Combined with a beat to beat finger cuff system for measurement of blood pressure, this machine produces core circulatory parameters continuously. Autonomic nervous function (BP variation, HR variation) and baroreflex sensitivity is also analysed.

Continuous measurement of peripheral oxygen saturation is registered with Masimo SET pulse oximeters.

13.4 Statistics

Responses with and without sildenafil will be compared within same individual. For parameters affected by calibration differences in machinery from test 1 to 2 delta values will be compared.

Power analysis:

Data from the main study allow estimations of anticipated results and statistical power. If the average of maximal RVSP during exercise in our group is 50 mmHg and sildenafil causes a 20% decrease in average to 40 mmHg (SD 10.0) a sample size of 13 patients leads to statistical power of 81.7% with 5% confidence level (calculation: DSS research 10.7.2008, http://www.dssresearch.com/toolkit/spcalc/power_a2.asp

Being tested
sildenafil citrate
Keywords
pulmonary hypertension, congenital heart defects, exercise, phosphodiesterase inhibitors, Exercise induced pulmonary arterial hypertensive response in congenital heart disease
Medical subject headings
Heart Defects, Congenital, Hypertension, Pulmonary, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • sildenafil citrateDrug

    capsule of 50 mg , 90 minutes before exercise study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Right ventricular pressure as measured by max velocity of tricuspid valve regurgitation

    Measured: baseline and max exercise

Secondary outcomes (2)
  1. DLco (lung diffusion test)

    Measured: baseline and max exercise

  2. cardiac output

    Measured: baseline and max exercise

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Oct 2008 (estimated)
  2. Study startSep 2008
  3. Primary completionFeb 2009 (estimated)
  4. Study completionApr 2009 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
15 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00772135
Sponsor's protocol ID
RH 2008 HR 2006 / 2 / 0012 TM
Other IDs
2006 / 2 / 0012
Status last verified
Oct 2008
First submitted
14 Oct 2008
Last updated
15 Oct 2008
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing sildenafil citrate in people with Congenital Heart Disease, run by Oslo University Hospital at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Oct 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Erik Thaulow, professor Dr Med (+47 23074537, erik.thaulow@rikshospitalet.no), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Right ventricular pressure as measured by max velocity of tricuspid valve regurgitation (time frame: baseline and max exercise). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2008.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in